These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

84 related articles for article (PubMed ID: 21707710)

  • 1. Na+/H+ exchanger regulatory factor 1 expression levels in blood and tissue predict breast tumour clinical behaviour.
    Bellizzi A; Mangia A; Malfettone A; Cardone RA; Simone G; Reshkin SJ; Paradiso A
    Histopathology; 2011 Jun; 58(7):1086-95. PubMed ID: 21707710
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Biological role of NHERF1 protein expression in breast cancer.
    Mangia A; Chiriatti A; Bellizzi A; Malfettone A; Stea B; Zito FA; Reshkin SJ; Simone G; Paradiso A
    Histopathology; 2009 Nov; 55(5):600-8. PubMed ID: 19912366
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Involvement of nuclear NHERF1 in colorectal cancer progression.
    Mangia A; Saponaro C; Malfettone A; Bisceglie D; Bellizzi A; Asselti M; Popescu O; Reshkin SJ; Paradiso A; Simone G
    Oncol Rep; 2012 Sep; 28(3):889-94. PubMed ID: 22766563
    [TBL] [Abstract][Full Text] [Related]  

  • 4. RhoA protein expression in primary breast cancers and matched lymphocytes is associated with progression of the disease.
    Bellizzi A; Mangia A; Chiriatti A; Petroni S; Quaranta M; Schittulli F; Malfettone A; Cardone RA; Paradiso A; Reshkin SJ
    Int J Mol Med; 2008 Jul; 22(1):25-31. PubMed ID: 18575772
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The prognostic value of the Na⁺/ H⁺ exchanger regulatory factor 1 (NHERF1) protein in cancer.
    Saponaro C; Malfettone A; Dell'Endice TS; Brunetti AE; Achimas-Cadariu P; Paradiso A; Mangia A
    Cancer Biomark; 2014; 14(2-3):177-84. PubMed ID: 24878819
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Suppression of breast cancer cell growth by Na+/H+ exchanger regulatory factor 1 (NHERF1).
    Pan Y; Wang L; Dai JL
    Breast Cancer Res; 2006; 8(6):R63. PubMed ID: 17078868
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Tissue microarray-based studies of patients with lymph node negative breast carcinoma show that met expression is associated with worse outcome but is not correlated with epidermal growth factor family receptors.
    Tolgay Ocal I; Dolled-Filhart M; D'Aquila TG; Camp RL; Rimm DL
    Cancer; 2003 Apr; 97(8):1841-8. PubMed ID: 12673709
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The role of STS and OATP-B mRNA expression in predicting the clinical outcome in human breast cancer.
    Al Sarakbi W; Mokbel R; Salhab M; Jiang WG; Reed MJ; Mokbel K
    Anticancer Res; 2006; 26(6C):4985-90. PubMed ID: 17214375
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Breast cancer-derived K172N, D301V mutations abolish Na+/H+ exchanger regulatory factor 1 inhibition of platelet-derived growth factor receptor signaling.
    Cheng S; Li Y; Yang Y; Feng D; Yang L; Ma Q; Zheng S; Meng R; Wang S; Wang S; Jiang WG; He J
    FEBS Lett; 2013 Oct; 587(20):3289-95. PubMed ID: 24012959
    [TBL] [Abstract][Full Text] [Related]  

  • 10. M34 actin regulatory protein is a sensitive diagnostic marker for early- and late-stage mammary carcinomas.
    Soriano Z; Pardee JD
    Clin Cancer Res; 2004 Jul; 10(13):4437-43. PubMed ID: 15240534
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Sentinel lymph node as a new marker for therapeutic planning in breast cancer patients.
    Gipponi M; Bassetti C; Canavese G; Catturich A; Di Somma C; Vecchio C; Nicolò G; Schenone F; Tomei D; Cafiero F
    J Surg Oncol; 2004 Mar; 85(3):102-11. PubMed ID: 14991881
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Prediction of tumour involvement in remaining axillary lymph nodes when the sentinel node in a woman with breast cancer contains metastases.
    Nos C; Harding-MacKean C; Fréneaux P; Trie A; Falcou MC; Sastre-Garau X; Clough KB
    Br J Surg; 2003 Nov; 90(11):1354-60. PubMed ID: 14598414
    [TBL] [Abstract][Full Text] [Related]  

  • 13. COX-2 expression in human breast carcinomas: correlation with clinicopathological features and prognostic molecular markers.
    Miglietta A; Toselli M; Ravarino N; Vencia W; Chiecchio A; Bozzo F; Motta M; Torchio B; Bocca C
    Expert Opin Ther Targets; 2010 Jul; 14(7):655-64. PubMed ID: 20536410
    [TBL] [Abstract][Full Text] [Related]  

  • 14. TGF-beta receptor 2 downregulation in tumour-associated stroma worsens prognosis and high-grade tumours show more tumour-associated macrophages and lower TGF-beta1 expression in colon carcinoma: a retrospective study.
    Bacman D; Merkel S; Croner R; Papadopoulos T; Brueckl W; Dimmler A
    BMC Cancer; 2007 Aug; 7():156. PubMed ID: 17692120
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Aberrant expression of 5-lipoxygenase-activating protein (5-LOXAP) has prognostic and survival significance in patients with breast cancer.
    Jiang WG; Douglas-Jones AG; Mansel RE
    Prostaglandins Leukot Essent Fatty Acids; 2006 Feb; 74(2):125-34. PubMed ID: 16364620
    [TBL] [Abstract][Full Text] [Related]  

  • 16. An immunohistochemical study of p21 and p53 expression in primary node-positive breast carcinoma.
    O'Hanlon DM; Kiely M; MacConmara M; Al-Azzawi R; Connolly Y; Jeffers M; Keane FB
    Eur J Surg Oncol; 2002 Mar; 28(2):103-7. PubMed ID: 11884043
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone marrow and lymph node assessment for minimal residual disease in patients with breast cancer.
    Diel IJ; Cote RJ
    Cancer Treat Rev; 2000 Feb; 26(1):53-65. PubMed ID: 10660491
    [TBL] [Abstract][Full Text] [Related]  

  • 18. p95HER-2 predicts worse outcome in patients with HER-2-positive breast cancer.
    Sáez R; Molina MA; Ramsey EE; Rojo F; Keenan EJ; Albanell J; Lluch A; García-Conde J; Baselga J; Clinton GM
    Clin Cancer Res; 2006 Jan; 12(2):424-31. PubMed ID: 16428482
    [TBL] [Abstract][Full Text] [Related]  

  • 19. LEA-135 expression: its association with a lower risk of recurrence and increased overall survival of patients with lymph node-positive primary invasive breast cancer.
    Saha B; Zhang N; Naritoku WY; Tsao-Wei DD; Groshen SL; Carlsson G; Larsson L; Gustavsson B; Chaiwun B; Taylor CR; Imam SA
    Anticancer Res; 2004; 24(4):2391-400. PubMed ID: 15330189
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Axillary lymph node metastases in patients with small carcinomas of the breast: is accurate prediction possible?
    Anan K; Mitsuyama S; Tamae K; Nishihara K; Iwashita T; Abe Y; Ihara T; Toyoshima S
    Eur J Surg; 2000 Aug; 166(8):610-5. PubMed ID: 11003428
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.